FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547257401> ?p ?o ?g. }

• W2547257401 endingPage "2257" @default.
• W2547257401 startingPage "2257" @default.
• W2547257401 abstract "Abstract Background Transfusion-dependent patients with severe cardiac siderosis often require intensive iron chelation therapy for a limited time to facilitate rapid removal of iron from the heart, allowing patients to move from a high-risk (cardiac T2*<10 ms) to lower risk (≥10 ms) status for heart failure. Oral deferasirox (DFX) monotherapy has been shown to improve cardiac T2*, but data on the combined use of DFX and deferoxamine (DFO) are limited. Aim To evaluate efficacy and safety of investigational DFX–DFO in combination followed by DFX monotherapy in patients with severe transfusional cardiac siderosis. Methods The prospective, Phase II, open-label, multinational HYPERION study evaluated DFX–DFO in combination followed by DFX monotherapy in transfusion-dependent patients with severe cardiac siderosis (NCT01254227). Patients enrolled were ≥10 years with CMR-measured cardiac T2* 5–<10 ms, left ventricular ejection fraction (LVEF) ≥56%, R2-MRI liver iron concentration (LIC) ≥7 mg Fe/g dw. Starting dose was DFX 20 mg/kg/d, 7 d/wk, plus DFO 40 mg/kg/d, 5 d/wk for ≥8 hrs/d. DFX dose could be increased to 30 and 40 mg/kg/d after Month 1 and 6, respectively. Patients achieving cardiac T2* ≥10 ms and a relative T2* increase of ≥10% from baseline (BL) any time after 6 months were switched to DFX monotherapy. Combination therapy was resumed if cardiac T2* fell to <10 ms with a relative decrease of ≥10% from previous T2* value. Dose adjustments were based on efficacy and safety parameters. Primary efficacy endpoint was change in geometric mean cardiac T2* at Month 12 divided by that at BL. A key secondary objective was the proportion of patients achieving T2* ≥10 ms and a ≥10% relative increase from BL after 6 and 12 months. Efficacy was analyzed for all evaluable patients in the full analysis set (FAS) who received ≥1 dose of study drug and had a BL and post-BL assessment; cardiac T2* is also reported for patients with T2* at BL and Month 12 (12-month completers). Results 60 patients were enrolled (59 β-thalassemia major, 1 Diamond–Blackfan anemia; mean age 22.8 years; 46.7% male) with severe iron overload (geometric mean [Gmean] cardiac T2* 7.03 ms, mean LIC 33.4 ± 14.5 mg Fe/g dw, median serum ferritin 5551 ng/mL [range 1163, 11,317]). Overall, 20 patients discontinued; 5 consent withdrawals, 4 adverse events (AEs: pruritus, arthritis, abdominal pain, drug rash with eosinophilia and systemic symptoms), 4 abnormal test procedure results (all T2* <5 ms), 4 lost to follow-up, 2 administrative problems, 1 death (central nervous system infection, suspected relationship to DFO). Mean dose was DFX 29.6 ± 6.3, 7 d/wk, and DFO 37.4 ± 5.8 mg/kg/d, 5 d/wk. In the evaluable FAS (n=52, last observation carried forward) cardiac T2* increased 9% and LIC decreased 46% (Fig); serum ferritin levels decreased by 2174 ng/mL (–6138, 1570). Among 12-month completers (n=36), cardiac T2* increased from 7.24 at BL to 8.24 ms (14% improvement). In patients with BL LIC <30 and ≥30 mg Fe/g dw, cardiac T2* improvement was 17% (7.85 to 9.15 ms, n=16) and 6% (6.69 to 7.11 ms, n=36), respectively. Overall, 12.5 and 19.2% of patients achieved T2* ≥10 ms and ≥10% relative increase from BL at Month 6 and 12, respectively. Mean LVEF remained stable and no patient had cardiac failure. AEs with suspected relationship to study drug (≥5%) were abdominal pain, nausea (both 6.7%); increased blood creatinine, diarrhea, increased urine protein/creatinine ratio (all 5.0%). 1 patient had serum creatinine >33% increase from BL and >upper limit of normal at 2 consecutive visits. Discussion Cardiac T2* improved during 12 months of treatment with DFX–DFO in patients with severe transfusional body iron burden. High BL LIC levels decreased considerably with DFX–DFO. Overall, as LIC decreased cardiac T2* increased, most notably after 6 months. The higher DFX dose permitted after Month 6 possibly influenced this trend. Cardiac T2* improvements were observed irrespective of BL LIC value, but were most marked in those with BL LIC <30 mg Fe/g dw, consistent with previous data showing that cardiac iron removal follows liver iron removal (Noetzli Blood 2008). Safety of DFX–DFO was consistent with established monotherapy profiles, with no unexpected findings. 2-year follow-up for HYPERION will evaluate the impact of longer-term DFX–DFO in combination on liver and cardiac iron removal. Disclosures: Aydinok: Shire: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau. Off Label Use: Deferasirox and deferoxamine are both indicated as a monotherapy for the treatment of chronic iron overload due to frequent blood transfusions. Patients with severe cardiac iron overload are at increased risk of heart failure and are often treated by off-label combination therapy for a limited time to facilitate rapid removal of iron from the heart, allowing patients to move to a lower-risk status. This abstract describes off-label use of the combination of deferasirox and deferoxamine to treat patients with severe transfusional cardiac iron overload. Kattamis:Novartis: Research Funding, Speakers Bureau; ApoPharma: Speakers Bureau. Cappellini:Genzyme: Honoraria; Novartis: Honoraria, Speakers Bureau. Perrotta:Novartis: Research Funding. Karakas:Novartis: Honoraria, Research Funding. Viprakasit:GPO, Thailand: Honoraria, Research Funding; Shire: Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau. Habr:Novartis: Employment. Wegener:Novartis: Employment. Shen:Novartis: Employment. Porter, MD on behalf of the HYPERION investigators:Shire: Consultancy, Honoraria; Celgene: Consultancy; Novartis: Consultancy, Honoraria, Research Funding." @default.
• W2547257401 created "2016-11-11" @default.
• W2547257401 creator A5001997857 @default.
• W2547257401 creator A5009338104 @default.
• W2547257401 creator A5030388617 @default.
• W2547257401 creator A5030898208 @default.
• W2547257401 creator A5030910487 @default.
• W2547257401 creator A5037746437 @default.
• W2547257401 creator A5045945097 @default.
• W2547257401 creator A5047560467 @default.
• W2547257401 creator A5049244658 @default.
• W2547257401 creator A5053053769 @default.
• W2547257401 creator A5058078318 @default.
• W2547257401 creator A5058130927 @default.
• W2547257401 creator A5069567664 @default.
• W2547257401 creator A5080150203 @default.
• W2547257401 date "2013-11-15" @default.
• W2547257401 modified "2023-10-12" @default.
• W2547257401 title "Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)" @default.
• W2547257401 doi "https://doi.org/10.1182/blood.v122.21.2257.2257" @default.
• W2547257401 hasPublicationYear "2013" @default.
• W2547257401 type Work @default.
• W2547257401 sameAs 2547257401 @default.
• W2547257401 citedByCount "5" @default.
• W2547257401 countsByYear W25472574012014 @default.
• W2547257401 countsByYear W25472574012019 @default.
• W2547257401 countsByYear W25472574012020 @default.
• W2547257401 crossrefType "journal-article" @default.
• W2547257401 hasAuthorship W2547257401A5001997857 @default.
• W2547257401 hasAuthorship W2547257401A5009338104 @default.
• W2547257401 hasAuthorship W2547257401A5030388617 @default.
• W2547257401 hasAuthorship W2547257401A5030898208 @default.
• W2547257401 hasAuthorship W2547257401A5030910487 @default.
• W2547257401 hasAuthorship W2547257401A5037746437 @default.
• W2547257401 hasAuthorship W2547257401A5045945097 @default.
• W2547257401 hasAuthorship W2547257401A5047560467 @default.
• W2547257401 hasAuthorship W2547257401A5049244658 @default.
• W2547257401 hasAuthorship W2547257401A5053053769 @default.
• W2547257401 hasAuthorship W2547257401A5058078318 @default.
• W2547257401 hasAuthorship W2547257401A5058130927 @default.
• W2547257401 hasAuthorship W2547257401A5069567664 @default.
• W2547257401 hasAuthorship W2547257401A5080150203 @default.
• W2547257401 hasConcept C126322002 @default.
• W2547257401 hasConcept C141071460 @default.
• W2547257401 hasConcept C2776517179 @default.
• W2547257401 hasConcept C2776672577 @default.
• W2547257401 hasConcept C2776999253 @default.
• W2547257401 hasConcept C2777799968 @default.
• W2547257401 hasConcept C2778198053 @default.
• W2547257401 hasConcept C2780883591 @default.
• W2547257401 hasConcept C2781053155 @default.
• W2547257401 hasConcept C71924100 @default.
• W2547257401 hasConcept C78085059 @default.
• W2547257401 hasConcept C90924648 @default.
• W2547257401 hasConceptScore W2547257401C126322002 @default.
• W2547257401 hasConceptScore W2547257401C141071460 @default.
• W2547257401 hasConceptScore W2547257401C2776517179 @default.
• W2547257401 hasConceptScore W2547257401C2776672577 @default.
• W2547257401 hasConceptScore W2547257401C2776999253 @default.
• W2547257401 hasConceptScore W2547257401C2777799968 @default.
• W2547257401 hasConceptScore W2547257401C2778198053 @default.
• W2547257401 hasConceptScore W2547257401C2780883591 @default.
• W2547257401 hasConceptScore W2547257401C2781053155 @default.
• W2547257401 hasConceptScore W2547257401C71924100 @default.
• W2547257401 hasConceptScore W2547257401C78085059 @default.
• W2547257401 hasConceptScore W2547257401C90924648 @default.
• W2547257401 hasIssue "21" @default.
• W2547257401 hasLocation W25472574011 @default.
• W2547257401 hasOpenAccess W2547257401 @default.
• W2547257401 hasPrimaryLocation W25472574011 @default.
• W2547257401 hasRelatedWork W1507673441 @default.
• W2547257401 hasRelatedWork W2004018092 @default.
• W2547257401 hasRelatedWork W2020966580 @default.
• W2547257401 hasRelatedWork W2062989112 @default.
• W2547257401 hasRelatedWork W2128293254 @default.
• W2547257401 hasRelatedWork W2293829826 @default.
• W2547257401 hasRelatedWork W2434406830 @default.
• W2547257401 hasRelatedWork W2572268349 @default.
• W2547257401 hasRelatedWork W2753536594 @default.
• W2547257401 hasRelatedWork W4223463122 @default.
• W2547257401 hasVolume "122" @default.
• W2547257401 isParatext "false" @default.
• W2547257401 isRetracted "false" @default.
• W2547257401 magId "2547257401" @default.
• W2547257401 workType "article" @default.